Abstract
Immune checkpoints negatively regulate immune cell responses. Programmed cell death protein 1:programmed death ligand 1 (PD-1:PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4):B7-1 are among the most important immune checkpoint pathways, and are key targets for immunotherapies that seek to modulate the balance between stimulatory and inhibitory signals to lead to favorable therapeutic outcomes. The current dogma of these two immune checkpoint pathways has regarded them as independent with no interactions. However, the newly characterized PD-L1:B7-1 ligand–ligand cis-interaction and its ability to bind CTLA-4 and CD28, but not PD-1, suggests that these pathways have significant crosstalk. Here, we propose that the PD-L1:B7-1 cis-interaction brings novel mechanistic understanding of these pathways, new insights into mechanisms of current immunotherapies, and fresh ideas to develop better treatments in a variety of therapeutic settings.
Original language | English (US) |
---|---|
Pages (from-to) | 207-219 |
Number of pages | 13 |
Journal | Trends in Molecular Medicine |
Volume | 27 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2021 |
Keywords
- B7-1
- CD28
- CTLA-4
- PD-1
- PD-L1
- cis-interaction
- immunotherapy
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology